Mirati Therapeutics | MRTX - Sales Revenues


Mirati Therapeutics reported $16.4M in Sales Revenues for its fiscal quarter ending in September of 2023.



Sales Change Date
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
Astellas Pharma JPY 537.93B 33.28B Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Bayer EUR 13.41B 1.97B Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Eisai JPY 205.43B 14.51B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Exelixis USD 610.8M 12.14M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
J&J USD 24.1B 500M Mar/2026
Merck USD 16.29B 110M Mar/2026
Moderna USD 389M 289M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Roche Holding CHF 15.65B 274.5M Dec/2025
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Takeda JPY 1.09T 100B Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026